2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1589

Impact of Osteoarthritis of the Hand on Disease Activity Scores and Health Status in Patients with Rheumatoid Arthritis
Abstract Number: 1287

Impact of Participation in Adalimumab Patient Support Program (PSP) on Clinical Outcomes and Predictors of PSP Utilization Among Patients with Rheumatoid Arthritis
Abstract Number: 2650

Impact of Patient Education on the Satisfaction of Rheumatoid Arthritis Patient : A Randomized Trial of Nurse-Led Vs. Physician-Led Education
Abstract Number: 3136

Impact of Prokinetic Agents on Systemic Sclerosis-Associated Gastrointestinal Disease: A Systematic Review
Abstract Number: 2488

Impact of Protocolized Tight Control and Biological Dose Optimization in Daily Clinical Practice: Results of a Pilot Implementation Study
Abstract Number: 508

Impact of Race on Patient Global Scores and the Misclassification of Disease Activity
Abstract Number: 1329

Impact of Repeating Imaging of the Sacroiliac Joints after One Year on the Classification of Patients According the ASAS Axial Spa Criteria
Abstract Number: 435

Impact of Sarilumab on Fatigue, Pain, Morning Stiffness, Productivity, and Health Related Quality of Life (HRQoL) in Patients with Active Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant of Anti-TNF-Î± Therapy: Results from a Phase 3 Study (RCT)
Abstract Number: 2173

Impact of Smoking on Patient-Reported Disease Status and Symptoms Among Women with Lupus
Abstract Number: 1874

Impact of Socioeconomic Status on Survival in Connective Tissue Disease Associated and Idiopathic Pulmonary Arterial Hypertension
Abstract Number: 2867

Impact of Timely Versus Delayed Use of Anti-Tumor Necrosis Factor (TNF) Biologics in the Treatment of Psoriatic Arthritis: Results from a Modeling Study
Abstract Number: 2771

Impact of Tocilizumab Monotherapy in Patients with Moderate to High Disease Activity: Real-World Analyses from the US Corrona Registry
Abstract Number: 2756

Impact of Tocilizumab Monotherapy on Patient-Reported Quality of Life Outcomes in the US Corrona Registry
Abstract Number: 2279

Impacts on Work: Arthritis Vs Chronic Joint Symptoms without Arthritis
Abstract Number: 1595

Impaired Coronary Flow Reserve in Rheumatoid Arthritis: A Robust Indicator of Cardiac Structure Associated with Systemic Inflammation and Rheumatoid Arthritis Treatments

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].